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ABSTRACT
Autoimmune diseases as well as type-I allergic diseases have markedly increased in the past 30 years. Envi-
ronmental estrogens or endocrine disruptors are possibly involved in the etiology of the increase in autoim-
mune diseases as one of environmental factors. In aged BWF1 mice, a murine model for SLE, B lymphocyte
chemoattractant (BLCCXCL13) is ectopically and highly expressed in target organs such as the thymus and
kidney. B1 cells, a specialized cell population that are distinguished from conventional B cells (B2 cells) by their
origin, cell surface phenotype, unique tissue distribution, self-reactivity, etc., preferentially migrate towards
BLC. Aberrant B1 cell trafficking to the target organs may result in activation of autoreactive CD4 T cells,
autoantibody production, and impaired mucosal immunity in the gut during the development of SLE. Interest-
ingly, B1 cells show a higher sensitivity to environmental estrogens than conventional B (B2) cells to produce
autoantibodies. Thus, B1 cell can be a useful target for evaluating the pathological significance of environ-
mental estrogens in the development of autoimmune diseases.
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INTRODUCTION
A recent epidemiological study has revealed that ap-
proximately one third of the Japanese population is
suffering from type-I allergic diseases including bron-
chial asthma, atopic dermatitis and allergic rhinitis.
Environmental rather than genetic factors are likely
involved in the marked increase in allergic diseases.
In addition to environmental factors which directly af-
fect the dose of allergens, it is pointed out that endo-
crine disruptors (ECDs) or environmental estrogens
may be involved in the marked increase in allergic
diseases.
It is well established that females have stronger im-
mune responses than males . This phenomenon of
gender-biased immune capability is largely attributed
to the effects of sex hormones on the immune sys-
tem.1,2 Estrogen regulates the synthesis of serum and
uterine IgM, IgA, and IgG and enhances antibody
production to several non-self and self antigens.3,4 It
is also well known that women are more susceptible
to autoimmune diseases than men. There is compel-
ling evidence, both in human and animals, that sex
hormones play a major role in autoimmune diseases,
particularly in lupus.5-7 The course of many autoim-
mune diseases is markedly affected during periods of
physiological fluctuation in sex hormones ( that is ,
pregnancy or menopause). Since many endocrine dis-
ruptors possess estrogenic activity, it is likely that the
effect of environmental estrogens, if any, would ap-
pear on the gender-biased diseases such as autoim-
mune diseases.8
On the other hand, another epidemiological study
has demonstrated that autoimmune diseases as well
as type-I allergic diseases have been markedly in-
creasing for the past 30 years (Fig. 1).9 It is generally
Allergology International. 2005;54:499-505
REVIEW ARTICLE
1Department of Molecular Preventive Medicine, School of Medi-
cine, The University of Tokyo, Japan.
Correspondence: Dr. Sho Ishikawa, Associate Professor, Depart-
ment of Molecular Preventive Medicine, School of Medicine, The
University of Tokyo, 7−3−1 Hongo, Bunkyo-ku, Tokyo 113−0033,
Japan.
Email: yamasho@m.u−tokyo.ac.jp
Received 23 March 2005.
2005 Japanese Society of Allergology
Allergology International Vol 54, No4, 2005 www.jsaweb.jp 499
Fig. 1 Marked increase of autoimmune diseases in Japan. Changes from.9 
The numbers of recipients of pension for intractable diseases including 
SLE (○), Myasthenia gravis (●), Dermatomyositis＋ Scleroderma (△), 
ITP (▲), malignant rheumatoid arthritis (□) have been increased for the 
past 30 years.
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believed that autoimmune diseases are caused by the
breakdown of immunological tolerance although the
precise mechanism remains unknown. SLE is a sys-
temic autoimmune disease characterized by produc-
tion of a variety of IgG autoantibodies including anti-
dsDNA Abs and massive immune complex deposition
in the glomeruli of the kidney.10-12 A marked mono-
nuclear cell infiltration in the target organs including
the kidney, thymus, and lung is another characteris-
tic in SLE. Recent advances in molecular and biologi-
cal analysis on chemokinechemokine receptors
have revealed pivotal roles of these proteins in inflam-
matory cellular infiltration. 13 Chemokines and their
receptors also play a pivotal role in linking innate im-
munity with acquired immunity through regulating
dendritic cell trafficking.14 Th1Th2 balance is regu-
lated by the chemokinechemokine receptor system
and dysregulation of the balance is a general feature
of the onset, progression, and prognosis of autoim-
mune diseases.15,16
Using BWF1 mice, a murine model for SLE, we
have demonstrated that aberrant B1 cell trafficking to
the target organs due to ectopic expression of BLC
CXCL13 plays an important role in the pathogenesis
of murine lupus.17-21
These findings in a murine model for SLE and the
epidemiological study showing a marked increase in
the number of SLE patients in Japan prompted us to
examine the effects of environmental estrogens on
B1 cells. Our study has revealed that B1, but not B2
cells are susceptible to environmental estrogens and
lead to the production of autoantibodies.22 Possible
roles of environmental estrogens in the development
of SLE and necessity of screening system specialized
for autoimmune diseases are discussed.
B1 CELLS IN INNATE AND ACQUIRED IM-
MUNITY
B1 cells were first described in 1983 by Hayakawa et
al.23,24 and suggested to be involved in the develop-
ment of autoimmune diseases. B1 cells in the perito-
neal cavity and spleen are increased in certain murine
autoimmune models including NZB, NZB.H2bm12,
moth-eaten mice and BWF1 mice. Likewise, elevated
levels of B1 cells have been documented in patients
with autoimmune disorders, notably in Sjgren’s syn-
drome and rheumatoid arthritis . 25,26 Furthermore ,
down-regulationelimination of B1 cells by either ad-
ministration of anti-IL-10 antibody27,28 or intraperito-
neal injection of distilled water delays the onset and
severity of lupus nephritis in BWF1 mice.29
It is further demonstrated that B1 cells are in-
volved in innate immunity by producing IgM antibod-
ies against microbial antigens including phosphatidyl-
choline (PC), lipopolysaccharide (LPS), and α (1―3)
dextran to eliminate blood borne-pathogens. IgM an-
tibody produced by B1 cells also plays a role for pre-
vention of certain viral infection.30 On the other hand,
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Fig. 2 Characteristics of B1 and B2 cels. B1 cels are distinct from 
conventional B cels (B2 cels) by their origin, tissue distribution, cel sur-
face phenotypes, antigen specificity and so on.
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Fig. 3 Ectopic high expression of BLC in the target organs in aged BWF1 mice and preferential 
chemotaxis of B1 cels towards BLC. Changes from.17(A) Cryosections of kidney and thymus ob-
tained from aged BWF1 mice were stained with goat anti-BLC polyclonal antibody (pAb) folowed 
by biotinylated rabbit anti-goat pAb and HRP-labeled streptavidin. (B) Spleen or peritoneal cels 
from young BWF1 mice were stained for FITC-labeled CD5 and PE-B220 and sorted into B1 and 
B2 cels. Chemotaxis assay using ChemoTx plate (Neuro Probe, Gaithersburg, MD, USA) was 
performed according to manufacturer’ sinstructions. Migrated cels were counted on a flow cy-
tometer under the constant flow rate.
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accumulating data suggest that B1 cells play an im-
portant role in mucosal immunity in the gut.31 Kroese
et al.32 previously reported that approximately half of
IgA+ B cells in the lamina propria in the intestinal mu-
cosa were derived from B1 cells . It has been also
demonstrated that B1 cells produce IgA antibody in
the presence of commensal microflora and contribute
to prevention of systemic invasion by intestinal bacte-
ria.33
Another important feature of B1 cells is their po-
tent antigen presenting ability.20,34 B1 cells stimulate
alloreactive CD4 T cells as effectively as splenic DCs.
Environmental Estrogens and B1 Cells
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Fig. 4 SLE as a chemokine disease. Aberant B1 cel traficking due to ectopic high expression 
of BLC in aged BWF1 mice results in activation of autoreactive CD4 T cels in the thymus, IgG 
autoantibody production presumably in the presence of folicular helper T cels (TFH), and impaired 
mucosal innate immunity in the gut. DC: dendritic cels, PPs: Peyer’ spatches, GALT: gut associ-
ated lymphoid tissues, M: macrophages 
The potent antigen presenting ability of B1 cells is
likely attributed to higher expression levels of acces-
sory molecules including CD80, CD86, and ICAM-1
than that in B2 cells. Lanzavecchia et al. 35 reported
that B cells could efficiently uptake the antigen
through their surface immunoglobulin receptors ,
process, and then present it to specific T cells in a
MHC-restricted manner. Since B1 cells often recog-
nize self-antigens with low affinity and broad specifici-
ties, B1 cells would efficiently activate auto-reactive
TCRs with low avidity. These findings suggest that
B1 cells play a pivotal role both in innate and ac-
quired immunity (Fig. 2).
ECTOPIC AND HIGH EXPRESSION OF B
LYMPHOCYTE CHEMOATTRACTANT (BLC
CXCL13) AND PATHOLOGICAL SIGNIFI-
CANCE OF B1 CELLS IN THE DEVELOP-
MENT OF SLE
B lymphocyte chemoattractant (BLCCXCL13) is
CXC chemokine which chemoattracts B cells and ac-
tivated CD4 T cells expressing CXCR5, a receptor for
BLC and is one of the homeostatic chemokines
which is essential for lymphogenesis.36―38 We found
that BLC is highly expressed in the target organs in-
cluding the thymus and kidney in aged BWF1 mice17
(Fig. 3A). Interestingly, BLC chemoattracts B1 cells
much more effectively than B2 cells probably due to
higher expression of CXCR5 on B1 cells than B2
cells17 (Fig. 3B). Ectopic and high expression of BLC
in the target organs was attributed to the accumula-
tion of mature myeloid DCs. The number of DCs in
the circulation was increased around 5 months of age
before the development of lupus nephritis and BLC
was induced when peripheral blood DCs were cul-
tured in the presence of TNF-α or IL-1β for 3 days.18
Ansel et al.39 demonstrated that BLC was essential
for B1 cell homing to the peritoneal cavity. Ectopic
high expression of BLC in the target organs in aged
BWF1 mice resulted in the defective B1 cell homing
to the peritoneal cavity and in preferential migration
of B1 cells to the target organs.19 BLC up-regulation
and B cell infiltration in the thymus was readily de-
tectable around 5 months of age before the establish-
ment of lupus nephritis. Furthermore, B1 cells acti-
vated autologous thymic CD4 T cells in vitro in the
presence of IL-2.20 The activation of thymic CD4 T
cells by B1 cells is MHC class II-dependent and there
is no TCR Vβ skewing in activated T cells. On the
other hand, CXCR5+CD4 T cells with similar pheno-
type to follicular helper T cells are increased in aged
BWF1 mice and enhance IgG anti-DNA antibody pro-
duction by B1 cells (unpublished data). These results
suggest that aberrant B1 cell trafficking to the target
organs due to ectopic and high expression of BLC
CXCL13 plays a pivotal role in the pathogenesis of
Ishikawa S
502 Allergology International Vol 54, No4, 2005 www.jsaweb.jp
Fig. 5 Direct efect of environmental estrogens on IgM antibody production by B1 cels. 
Changes from.22 B1 or B2 cels obtained from young or aged BWF1 mice were cultured in 
the presence of E2 (100 nM), DES (100 nM), BPA (1 uM) or NP (1 uM) for 4 days, and the 
amount of total IgM in the culture supernatants were determined by ELISA. *p＜0.05, **p
＜0.01.
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Fig. 6 B1 cels as a useful tool for evaluating the patho-
genic efect of environmental estrogens on autoimmune 
diseases. 
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murine SLE (Fig. 4).
HIGHER SUSCEPTIBILITY OF B1 CELLS TO
ENDOCRINE DISRUPTORS THAN B2 CELLS
Because SLE has been markedly increasing for the
past 30 years and B1 cells play a pivotal role in the
pathogenesis of murine SLE, it is tempting to specu-
late that B1 cells are possible targets for environ-
mental estrogens. Indeed, IgM antibody production
by B1 cells was significantly enhanced when cultured
with estradiol (E2 ) , Diethylstilbestrol (DES ) , or
BisphenolA (BPA) (Fig. 5). Interestingly, B1 cells de-
rived from aged BWF1 mice developing lupus nephri-
tis showed a higher response to environmental estro-
gens than those from young BWF1 mice. This is pre-
sumably due to higher expression of ER-α in B1 cells
derived from aged BWF 1 mice than those from
young BWF1 mice. It was noted that environmental
estrogens did not affect B2 cells at all. An enhancing
effect of environmental estrogens including DES and
BPA on autoantibody production was further con-
firmed in vivo. E2, DES, and BPA implanted subcuta-
neouly in silastic tubes enhanced autoantibody pro-
duction to bromelain-treated RBC. It was previously
demonstrated that anti-Br-RBC Ab was mainly pro-
duced by B1 cells.40 Implanted E2 and DES, but not
BPA also enhanced IgG anti-dsDNA antibody produc-
tion as well as IgG deposition in the glomeruli in the
kidney. The failure of BPA to enhance IgG autoanti-
body production is likely attributed to weak estro-
genic activity of BPA . 41 The estrogen level in di-
estrous female mice is around 20―30 pgml and in-
creases to 100―200 pgml during estrus. It reaches to
5,000―10,000 pgml during pregnancy. Therefore, the
serum levels of E2 in mice implanted with E2 silastic
tubes are in the middle of those values between es-
trus and pregnancy. Long lasting release of BPA from
implanted tubes was also observed although BPA
concentration in the serum was much higher than
that expected from environmental exposure in hu-
man population .Analysis of gene expression using
DNA microarray will provide useful information that
can be used to establish a screening system for envi-
ronmental estrogens which may be involved in
autoantibody production by B1 cells and to evaluate
the pathological significance of those in the develop-
Environmental Estrogens and B1 Cells
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ment of autoimmune diseases.
CONCLUDING REMARKS
Environmental estrogens may possibly contribute to
the marked increase in type-I allergic and autoim-
mune diseases. However, it is difficult to clarify the
causality between environmental estrogens and dis-
eases because it becomes evident only very slowly
and indiscriminately. We should be ready to start a
new strategy to protect human health from these
kind of threats before it becomes too late. Hopefully,
B1 cells will provide a good target to evaluate the bio-
logical significance of environmental estrogens in the
development of autoimmune diseases (Fig. 6).
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